Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Influence of a dopamine pathway additive genetic efficacy score on smoking cessation: results from two randomized clinical trials of bupropion.

Addiction (Abingdon, England) - 1 Dec 2013

David Sean P, Strong David R, Leventhal Adam M, Lancaster Molly A, McGeary John E, Munafò Marcus R, Bergen Andrew W, Swan Gary E, Benowitz Neal L, Tyndale Rachel F, Conti David V, Brown Richard A, Lerman Caryn, Niaura Raymond

Abstract excerpt

AIMS: To evaluate the associations of treatment and an additive genetic efficacy score (AGES) based on dopamine functional polymorphisms with time to first smoking lapse and point prevalence abstinence at end of treatment among participants enrolled into two randomized clinical trials of smoking cessation therapies. DESIGN: Double-blind pharmacogenetic efficacy trials randomizing participants to active or placebo...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bupropion
Share to Cognitive Behavioral Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Combined Modality Therapy

Share to Dopamine Plasma Membrane Transport Proteins

Share to Dopamine Uptake Inhibitors

Share to Double-Blind Method

Share to Receptors, Dopamine D4

Share to Smoking Cessation

Source

Open in PubMed Open full text

Identifiers

PMID: 23941313
DOI: 10.1111/add.12325
PMCID: PMC3834197

Genes

DRD4
COMT

Variants

rs1800497

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Influence of a dopamine pathway additive genetic efficacy score on smoking cessation: results from two randomized clinical trials of bupropion.PMID 23941313Read ↗

Dopamine D4 receptor gene variation moderates the efficacy of bupropion for smoking cessation.Semantic proximity Read ↗

Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessationSemantic proximity Read ↗

Smoking Cessation Pharmacogenetics: Analysis of Varenicline and Bupropion in Placebo-Controlled Clinical TrialsSemantic proximity Read ↗

Nicotinic acetylcholine receptor variation and response to smoking cessation therapies.Semantic proximity Read ↗

Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials.Semantic proximity Read ↗

Drugs and genotypes: how pharmacogenetic information could improve smoking cessation treatment.Semantic proximity Read ↗

Genetic variation in the dopamine pathway and smoking cessation.Semantic proximity Read ↗

Effect of genetic polymorphisms on smoking cessation: a trial of bupropion in Korean male smokers.Semantic proximity Read ↗

Markers in the 15q24 nicotinic receptor subunit gene cluster (CHRNA5-A3-B4) predict severity of nicotine addiction and response to smoking cessation therapy.Semantic proximity Read ↗

Organic cation transporter variation and response to smoking cessation therapies.Semantic proximity Read ↗

The association of dopamine pathway gene score, nicotine dependence and smoking cessation in a rural male population of Shandong, China.Semantic proximity Read ↗

Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.